Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

NCT02405585 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
Pancreatic Carcinoma Non-resectable

Interventions

DRUG: mFOLFIRINOX
BIOLOGICAL: Algenpantucel-L Immunotherapy
RADIATION: SBRT
DRUG: Gemcitabine

Sponsor

NewLink Genetics Corporation